214 related articles for article (PubMed ID: 36733378)
1. Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition.
Beaudoin JJ; Yang K; Adiwidjaja J; Taneja G; Watkins PB; Siler SQ; Howell BA; Woodhead JL
Front Pharmacol; 2022; 13():1085621. PubMed ID: 36733378
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.
Aleo MD; Shah F; He K; Bonin PD; Rodrigues AD
Chem Res Toxicol; 2017 May; 30(5):1219-1229. PubMed ID: 28437613
[TBL] [Abstract][Full Text] [Related]
3. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
4. 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity.
Zhao G; Xu D; Yuan Z; Jiang Z; Zhou W; Li Z; Yin M; Zhou Z; Zhang L; Wang T
Toxicology; 2017 Jul; 386():40-48. PubMed ID: 28552422
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4.
Yoshikado T; Takada T; Yamamoto T; Yamaji H; Ito K; Santa T; Yokota H; Yatomi Y; Yoshida H; Goto J; Tsuji S; Suzuki H
Mol Pharmacol; 2011 Feb; 79(2):241-50. PubMed ID: 21056966
[TBL] [Abstract][Full Text] [Related]
6. Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites.
Yoshikado T; Takada T; Yamamoto H; Tan JK; Ito K; Santa T; Suzuki H
Mol Pharmacol; 2013 Feb; 83(2):552-62. PubMed ID: 23220748
[TBL] [Abstract][Full Text] [Related]
7. Role of Multidrug Resistance Protein 3 in Antifungal-Induced Cholestasis.
Mahdi ZM; Synal-Hermanns U; Yoker A; Locher KP; Stieger B
Mol Pharmacol; 2016 Jul; 90(1):23-34. PubMed ID: 27112167
[TBL] [Abstract][Full Text] [Related]
8. Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.
Woodhead JL; Yang K; Siler SQ; Watkins PB; Brouwer KL; Barton HA; Howell BA
Front Pharmacol; 2014; 5():240. PubMed ID: 25426072
[TBL] [Abstract][Full Text] [Related]
9. Secretin activation of the apical Na+-dependent bile acid transporter is associated with cholehepatic shunting in rats.
Alpini G; Glaser S; Baiocchi L; Francis H; Xia X; Lesage G
Hepatology; 2005 May; 41(5):1037-45. PubMed ID: 15834929
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (-/-) mice.
Smith AJ; de Vree JM; Ottenhoff R; Oude Elferink RP; Schinkel AH; Borst P
Hepatology; 1998 Aug; 28(2):530-6. PubMed ID: 9696021
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4.
Köck K; Ferslew BC; Netterberg I; Yang K; Urban TJ; Swaan PW; Stewart PW; Brouwer KL
Drug Metab Dispos; 2014 Apr; 42(4):665-74. PubMed ID: 24154606
[TBL] [Abstract][Full Text] [Related]
13. Liver pathology in severe multidrug resistant 3 protein deficiency: a series of 10 pediatric cases.
Vij M; Safwan M; Shanmugam NP; Rela M
Ann Diagn Pathol; 2015 Oct; 19(5):277-82. PubMed ID: 26117383
[TBL] [Abstract][Full Text] [Related]
14. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes.
Trauner M; Fickert P; Wagner M
Semin Liver Dis; 2007 Feb; 27(1):77-98. PubMed ID: 17295178
[TBL] [Abstract][Full Text] [Related]
15. Alterations of canalicular ATP-binding cassette transporter expression in drug-induced liver injury.
Zollner G; Thueringer A; Lackner C; Fickert P; Trauner M
Digestion; 2014; 90(2):81-8. PubMed ID: 25196354
[TBL] [Abstract][Full Text] [Related]
16. The C-DILI™ Assay: An Integrated In Vitro Approach to Predict Cholestatic Hepatotoxicity.
Jackson JP; Brouwer KR
Methods Mol Biol; 2019; 1981():75-85. PubMed ID: 31016648
[TBL] [Abstract][Full Text] [Related]
17. Bile Duct Injury due to Drug Induced Liver Injury.
Grewal P; Ahmad J
Curr Hepatol Rep; 2019; 18(3):269-273. PubMed ID: 33134030
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.
Nakamuta M; Fujino T; Yada R; Yasutake K; Yoshimoto T; Harada N; Yada M; Higuchi N; Kato M; Kohjima M; Taketomi A; Maehara Y; Nishinakagawa T; Machida K; Matsunaga K; Nakashima M; Kotoh K; Enjoji M
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):22-8. PubMed ID: 20040336
[TBL] [Abstract][Full Text] [Related]
19. Impact of hypoxia and AMPK on CFTR-mediated bicarbonate secretion in human cholangiocyte organoids.
Roos FJM; Bijvelds MJC; Verstegen MMA; Roest HP; Metselaar HJ; Polak WG; Jonge HR; IJzermans JNM; van der Laan LJW
Am J Physiol Gastrointest Liver Physiol; 2021 May; 320(5):G741-G752. PubMed ID: 33655768
[TBL] [Abstract][Full Text] [Related]
20. Development of an in vitro cholestatic drug-induced liver injury evaluation system using HepG2-hNTCP-C4 cells in sandwich configuration.
Sakai Y; Okumura H; Iwao T; Watashi K; Ito K; Matsunaga T
Toxicol In Vitro; 2019 Dec; 61():104619. PubMed ID: 31394163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
